Revlimid prices U.S. vs select countries 2020

In 2020, both the estimated U.S. net price and gross price for a one-month supply (28 capsules) of Revlimid Oral Capsule (10mg) were over four times higher than gross prices paid in Australia. In comparison, while less extreme, U.S. prices of Revlimid were still over 2.5 times higher than Canadian. Revlimid is an immunomodulatory drug used to treat Multiple Myeloma (blood cancer) or anemia in patients with myelodysplastic syndrome. This statistic shows Revlimid's net and gross prices in the United States compared to gross prices in Australia and Canada as of 2020.

Estimated U.S. prices of Revlimid compared to prices in Australia and Canada as of 2020*

Characteristic	Price in U.S. dollars
U.S. gross price	22,008
U.S. estimated net price	21,375
Australia gross price	4,941
Canada (Ontario) gross price	8,193

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

March 2021

More information

Region

Australia, Canada, United States

Survey time period

as of January 2020

Supplementary notes

* Prices are for a monthly supply of Revlimid Oral Capsule 10mg (28 capsules).
Estimated U.S. net prices reflect confidential rebates and other price concessions, information on such discounts was not publicly available for the comparison countries. Thus, the actual differences between U.S. prices and those of the other countries were likely larger than GAO estimates in this statistic.

Prices for selected comparison countries—Australia and Canada (Ontario)—were prices listed on their respective public formularies from January 2020 and were converted to U.S. dollars at the relevant monthly Federal Reserve rates.

Citation formats